philipn authored on Oct. 13, 2020, 9:36 p.m. You can also use the and keys
| | Additions are marked like this |
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19. In an abstract published in October, 2020, fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients: 152 participants were randomized in the modified intention to treat group. No patients (0/80, 0%) in the fluvoxamine group clinically deteriorated, compared to 8.3% (6/72) in the placebo group (logrank chi-square 6.8, p=0.009). See also |
